Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Last updated: April 29, 2024
Sponsor: M.D. Anderson Cancer Center
Overall Status: Completed

Phase

4

Condition

Neoplasms

Treatment

Magnetic Resonance Imaging

Fludeoxyglucose F-18

Positron Emission Tomography

Clinical Study ID

NCT05054998
2017-0435
NCI-2019-02459
2017-0435
  • Ages > 18
  • All Genders

Study Summary

This phase IV trial studies how well delaying positron emission tomography (PET)/magnetic resonance imaging (MRI) scan after injection of fluorodeoxyglucose (FDG) can improve the imaging of patients with cancer that has spread to brain (brain metastases). FDG is a type of imaging agent that doctors use to help "see" the images on a scan more clearly. Delaying PET/MRI scan after injecting FDG may improve how well doctors can tell the difference between healthy and unhealthy tissue.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pre-treatment adult patients with any solid organ metastasis and at least threeintraaxial brain metastases including at least one enhancing > 10 mm lesion
  • Rim or solid enhancing lesion(s) WITH a history of non-central nervous system (CNS)pathologic proven metastatic disease will be considered as a consensus between thereferring radiation oncologist or neurosurgeon and a neuroradiology
  • Planned surgery or radiation to the metastases
  • Ability to undergo PET magnetic resonance (MR) examination

Exclusion

Exclusion Criteria:

  • Known allergy to FDG or gadolinium based contrast agents
  • History of impaired renal function (glomerular filtration rate [GFR] < 30)
  • Pregnant women are excluded

Study Design

Total Participants: 12
Treatment Group(s): 3
Primary Treatment: Magnetic Resonance Imaging
Phase: 4
Study Start date:
August 03, 2018
Estimated Completion Date:
April 26, 2024

Study Description

PRIMARY OBJECTIVE:

I. To assess the optimal fludeoxyglucose F-18 (fluorodeoxyglucose) positron emission tomography (FDG PET) imaging time post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma (measured as lesion/background [L/B] ratio) in patients with brain metastasis.

SECONDARY OBJECTIVE:

I. To identify genotypic factors in FDG tumor metabolism derived from metrics, including maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), mean tumor volume (MTV), and L/B ratio.

EXPLORATORY OBJECTIVES:

I. To identify patterns of metabolism derived from metrics, such as SUVmax, SUVmean, TLG, MTV, and L/B ratio, and magnetic resonance imaging metrics, such as regional perfusion abnormalities, apparent diffusion coefficient values, fractional diffusivity measures, and magnetic resonance spectroscopic finding.

II. To identify if post treatment changes in lesion metabolism from baseline correlate with treatment success.

OUTLINE:

Patients receive fludeoxyglucose F-18 intravenously (IV) over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.